Showing that inhibition of CCL2 substantially decreased PCa growth, and associated aggressive phenotype in animal models, Zhang et al. proposed that targeting CCL2 in the tumor microenvironment may be an attractive therapeutic target in metastatic PCa. The gene discussed is CCL2; the disease is neoplasm.